Identification of P450 Enzymes Involved in Metabolism of Verapamil in Humans

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1993 Sep 1

PMID 8232610

Citations 39

Authors

H K Kroemer

J C GAUTIER

P Beaune

C Henderson

C R Wolf

M Eichelbaum

Affiliations

Soon will be listed here.

Abstract

The calcium channel blocker verapamil[2,8-bis-(3,4-dimethoxyphenyl)-6-methyl-2-isopropyl-6- azaoctanitrile] is widely used in the treatment of hypertension, angina pectoris and cardiac arrhythmias. The drug undergoes extensive and variable hepatic metabolism in man with the major metabolic steps comprising formation of D-617 [2-(3,4-dimethoxyphenyl)-5-methylamino-2-isopropylvaleronitrile] and norverapamil [2,8-bis-(3,4-dimethoxyphenyl)-2-isopropyl-6-azaoctanitrile]. The enzymes involved in metabolism of verapamil have not been characterized so far. Identification of these enzymes would enable estimation of both interindividual variability in verapamil metabolism introduced by the respective pathway and potential for metabolic interactions. We therefore characterized the enzymes involved in formation of D-617 and norverapamil. The maximum rate of formation of D-617 and norverapamil was determined in the microsomal fraction of 21 human livers which had been previously characterized for the individual expression of various P450 enzymes (CYP1A2, CYP2C, CYP2D6, CYP2E1 and CYP3A3/4) by means of Western blotting. Specific antibodies directed against CYP3A were used to inhibit formation of D-617 and norverapamil. Finally, formation of both metabolites was investigated in microsomes obtained from yeast cells which were genetically engineered for stable expression of human P450. Formation of D-617 was correlated with the expression of CYP3A (r = 0.85; P < 0.001) and CYP1A2 (r = 0.57; P < 0.01) in the microsomal fraction of 21 human livers after incubation with racemic verapamil.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Performance and Sensitivity of [Tc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver.

Hernandez-Lozano I, Leterrier S, Mairinger S, Stanek J, Zacher A, Breyer L Mol Pharm. 2024; 21(2):932-943.

PMID: 38225758 PMC: 10848257. DOI: 10.1021/acs.molpharmaceut.3c01036.

Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.

Marie S, Frost K, Hau R, Martinez-Guerrero L, Izu J, Myers C Acta Pharm Sin B. 2023; 13(1):1-28.

PMID: 36815037 PMC: 9939324. DOI: 10.1016/j.apsb.2022.08.018.

Pharmacogenetics in Primary Headache Disorders.

Belyaeva I, Subbotina A, Eremenko I, Tarasov V, Chubarev V, Schioth H Front Pharmacol. 2022; 12:820214.

PMID: 35222013 PMC: 8866828. DOI: 10.3389/fphar.2021.820214.

Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.

Klomp F, Wenzel C, Drozdzik M, Oswald S Pharmaceutics. 2020; 12(12).

PMID: 33322313 PMC: 7764576. DOI: 10.3390/pharmaceutics12121201.

Impact of switching to a heat-not-burn tobacco product on CYP1A2 activity.

van der Plas A, Pouly S, Blanc N, Haziza C, de La Bourdonnaye G, Titz B Toxicol Rep. 2020; 7():1480-1486.

PMID: 33204648 PMC: 7649435. DOI: 10.1016/j.toxrep.2020.10.017.

References

Brian W, Sari M, Iwasaki M, Shimada T, Kaminsky L, Guengerich F . Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry. 1990; 29(51):11280-92. DOI: 10.1021/bi00503a018. View

Sesardic D, Boobis A, Murray B, Murray S, Segura J, de la Torre R . Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol. 1990; 29(6):651-63. PMC: 1380167. DOI: 10.1111/j.1365-2125.1990.tb03686.x. View

Watkins P, Wrighton S, Maurel P, Schuetz E, Parker G, Guzelian P . Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A. 1985; 82(18):6310-4. PMC: 391043. DOI: 10.1073/pnas.82.18.6310. View

Lubet R, Mayer R, CAMERON J, Nims R, Burke M, Wolff T . Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch Biochem Biophys. 1985; 238(1):43-8. DOI: 10.1016/0003-9861(85)90138-9. View

Barbarash R, Bauman J, Fischer J, Kondos G, Batenhorst R . Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. Chest. 1988; 94(5):954-9. DOI: 10.1378/chest.94.5.954. View

Ayesh R, Kroemer H, Eichelbaum M, Smith R . Metabolism of verapamil in a family pedigree with deficient N-oxidation of trimethylamine. Br J Clin Pharmacol. 1991; 31(6):693-6. PMC: 1368582. DOI: 10.1111/j.1365-2125.1991.tb05595.x. View

Omura T, Sato R . THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem. 1964; 239:2370-8. View

Fuhr U, Woodcock B, Siewert M . Verapamil and drug metabolism by the cytochrome P450 isoform CYP1A2. Eur J Clin Pharmacol. 1992; 42(4):463-4. DOI: 10.1007/BF00280138. View

Meier P, MUELLER H, Dick B, Meyer U . Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology. 1983; 85(3):682-92. View

10.

Cashman J . Enantioselective N-oxygenation of verapamil by the hepatic flavin-containing monooxygenase. Mol Pharmacol. 1989; 36(3):497-503. View

11.

Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J . Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 1992; 6(2):752-8. DOI: 10.1096/fasebj.6.2.1371482. View

12.

Towbin H, Staehelin T, Gordon J . Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979; 76(9):4350-4. PMC: 411572. DOI: 10.1073/pnas.76.9.4350. View

13.

Botsch S, GAUTIER J, Beaune P, Eichelbaum M, Kroemer H . Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993; 43(1):120-6. View

14.

Guengerich F, Dannan G, Wright S, Martin M, Kaminsky L . Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. Biochemistry. 1982; 21(23):6019-30. DOI: 10.1021/bi00266a045. View

15.

Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer H . Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther. 1990; 253(3):1042-8. View

16.

Kroemer H, Echizen H, Heidemann H, Eichelbaum M . Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther. 1992; 260(3):1052-7. View

17.

Rutledge D, Pieper J, Mirvis D . Effects of chronic phenobarbital on verapamil disposition in humans. J Pharmacol Exp Ther. 1988; 246(1):7-13. View

18.

McTavish D, Sorkin E . Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1989; 38(1):19-76. DOI: 10.2165/00003495-198938010-00003. View

19.

Eichelbaum M, Ende M, Remberg G, SCHOMERUS M, DENGLER H . The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos. 1979; 7(3):145-8. View

20.

Lindholm A, Henricsson S . Verapamil inhibits cyclosporin metabolism. Lancet. 1987; 1(8544):1262-3. DOI: 10.1016/s0140-6736(87)92710-3. View